This is a free sample of content from Cytokines: From Basic Mechanisms of Control to New Therapeutics. Click here for more information on how to buy the book. Index A Cryopyrin-associated periodic syndromes (CAPS), AKT 262–263 g chain family cytokine signaling, 9 CTCL. See Cutaneous T-cell lymphoma T-cell development role, 279 Cutaneous T-cell lymphoma (CTCL), interleukin-15 role, AMPs. See Antimicrobial peptides 448 Antimicrobial peptides (AMPs), 456 Cytokine release syndrome (CRS), interleukin-6 therapeutic Arid5a, 94 targeting, 93, 94 Atopic dermatitis Cytokine studies interleukin-17 studies, 130 agonist development, 458–459 interleukin-22 therapeutic targeting, 169 alarmins, 456–457 antagonist development, 459–460 assay development, 457 B definition, 455–456 B cell historical perspective, 456 g chain family cytokine function, 16–18 mimics, 457 interferon-g in activation, 226–227 mutation studies, 458 tumor necrosis factor in development and function, 105 signaling studies, 457–458 BCL11B, 280–281 b Common family cytokines. See also specific cytokines cancer studies, 46 D functions, 43–44 Daclizumab, 21 nervous system function, 46–47 DC. See Dendritic cell overview, 40–43 Dendritic cell (DC) receptors classical dendritic cells activation, 48–49, 51 cDC1 development and function, 397–398 assembly, 48 cDC2 development and function, 398–399 assembly, 48–51 GM-DCs, 403–404 interactions with other receptors, 47–48 human cell features, 401–402 proximal activation of signaling, 52–53 identification sepsis and inflammation studies, 44–45 mouse bone marrow, 396–397 therapy, 41–42, 53–56 surface markers for in vivo identification, 403 BLIMP1, 15 maturation, 404–406 Briakinumab, 151 Mo-DCs, 403 g chain family cytokine function, 19 C interferon-g in activation, 226 Candida albicans, interleukin-17 studies, 129 long noncoding RNA regulation of differentiation, CAPS. See Cryopyrin-associated periodic syndromes 297–298 Castleman disease, toclizumab therapy, 89 plasmacytoid dendritic cells CD. See Crohn’s disease development and function, 399–400 Ciliary neurotrophic factor (CNTF) human cell features, 402 overview, 72–73 subsets, 395 mutations and disease, 76 Diabetes type 1, g chain family cytokine studies, 20–21 trans-signaling, 75 Diabetic foot ulcer (DFU), interleukin-20 family member CISH, 317–318 therapy, 174–175 CNTF. See Ciliary neurotrophic factor Crohn’s disease (CD) g chain family cytokine studies, 20 E interleukin-10 studies, 159, 161–162 Ectodysplasin, 104 interleukin-22 therapy, 170–172 EPO. See Erythropoietin CRS. See Cytokine release syndrome Erythropoietin (EPO), receptor, 47–48 463 © 2018 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Cytokines: From Basic Mechanisms of Control to New Therapeutics. Click here for more information on how to buy the book. Index F IFN-a. See Interferon-a Familial Mediterranean fever (FMF), 263–264 IFN-g. See Interferon-g FGK 4.5, 444 IL-1. See Interleukin-1 FMF. See Familial Mediterranean fever IL-2. See Interleukin-2 Follicular lymphoma, interferon-a therapy, 437 IL-3. See Interleukin-3 FOXP3, 11, 332 IL-4. See Interleukin-4 IL-5. See Interleukin-5 G IL-6. See Interleukin-6 g Chain family cytokines. See also specific cytokines IL-7. See Interleukin-7 autoimmune disease role, 19–22 IL-9. See Interleukin-9 B-cell function, 16–18 IL-10. See Interleukin-10 gene expression mediation, 9–10 IL-11. See Interleukin-11 natural killer cell function, 18–19 IL-12. See Interleukin-12 overview, 1–5 IL-13. See Interleukin-13 receptors, 5–7 IL-15. See Interleukin-15 signaling, 7–9 IL-17. See Interleukin-17 structure, 2 IL-19. See Interleukin-19 T-cell function IL-20. See Interleukin-20 CD8þ T-cell development and differentiation, 16 IL-21. See Interleukin-21 development, 10–11 IL-22. See Interleukin-22 helper T-cell differentiation, 12–16 IL-23. See Interleukin-23 Tregs, 11–12 IL-24. See Interleukin-24 therapy, 22–25 IL-26. See Interleukin-26 GATA3 IL-28. See Interleukin-28 helper T cells IL-29. See Interleukin-29 differentiation role, 330–332 IL-33. See Interleukin-33 expression by noncanonical Th cell subtypes, IL-37. See Interleukin-37 332–333 ILC. See Innate lymphoid cell T-cell development role, 273–274, 277–280 Inflammation GCA. See Giant cell arteritis autoinflammatory disease. See Interleukin-1 Giant cell arteritis (GCA), toclizumab therapy, 92 b common family cytokine studies, 44–45 GM-CSF. See Granulocyte macrophage colony-stimulating granulocyte macrophage colony-stimulating factor factor role, 45 Graft-versus-host disease (GVHD), interleukin-22 interleukin-17 studies protective effects, 173–174 IL-17B, 131 Granulocyte macrophage colony-stimulating factor IL-17C, 131–132 (GM-CSF) IL-17D, 132 cancer immunotherapy, 439–440 IL-17E, 132 cancer studies, 46 tumor microenvironment, 414 functional overview, 43–44 tumor necrosis factor role, 103 nervous system function, 46–47 Innate lymphoid cell (ILC) receptor, 48–53 cytokine regulation sepsis and inflammation role, 45 group 1 cells, 382–383 therapeutic targeting, 53–55 group 2 cells, 383–385 GVHD. See Graft-versus-host disease group 3 cells, 385–387 interferon, 382–383 H interleukin-1, 387 HEB, T-cell development role, 280–281 interleukin-2, 381–382, 386 Hepatitis interleukin-4, 384–385 interferon-g therapy, 176 interleukin-5, 384, 389 interleukin-22 protective effects, 173 interleukin-7, 381–382, 386 HHV8. See Human herpes virus 8 interleukin-9, 384–385 Human herpes virus 8 (HHV8), interleukin-6, 73 interleukin-12, 388 interleukin-13, 384 interleukin-15, 381–382 I interleukin-17, 386–387 ID2, 400 interleukin-22, 386–387 IFN. See Interferon overview, 380–382 464 © 2018 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Cytokines: From Basic Mechanisms of Control to New Therapeutics. Click here for more information on how to buy the book. Index plasticity modulation, 387–388 interleukin-1 receptor antagonist deficiency, 265 tumor immunity, 388–389 intrinsic inflammasomopathies, 261–265 functional overview, 379–380 Majeed syndrome, 265 subsets, 380 mevalonate kinase deficiency, 266 Th cell relationship, 335–336 NLRC4-associated autoinflammatory Innate repair receptor (IRR), 47–48 diseases, 264 Interferon (IFN) NLRP12-associated autoinflammatory cancer studies, 197 disorder, 265 classes, 203–204, 206 overview, 261 classification, 436 pyogenic arthritis, pyoderma gangrenosum and innate lymphoid cell regulation, 382–383 acne syndrome, 265–266 long noncoding RNA regulation, 302–303 tumor necrosis factor receptor-associated periodic signaling, 196–197, 205 syndrome, 267 Interferon-a (IFN-a), cancer immunotherapy cellular sources, 240–241 follicular lymphoma, 437 expression regulation, 246 Kaposi sarcoma, 437 family members, 239, 255–256 melanoma, 437–438 immune regulation, 245–246 toxicity, 438 immune stimulation by inflammasome-dependent Interferon-g (IFN-g) cytokines, 260 antibodies, 457 inflammasome-dependent processing, 256–260 cancer immunoediting role innate lymphoid cell regulation, 387 elimination phase, 229–231 nuclear function, 248 equilibrium, 231–232 overview, 239–240 escape, 232–233 signaling regulation, 247–248 overview, 227–229 Interleukin-2 (IL-2) cancer studies, 176–177 autoimmune disease studies, 19–22 cellular sources, 220–221 cancer immunotherapy gene, 219 low-dose trials, 435–436 immune cell activation melanoma, 434–435 B cell, 226–227 overview, 433–434 dendritic cell, 226 renal cell carcinoma, 434–435 macrophage, 225–226 CD8þ T cell T cells function, 16 CD8þ T cells, 227 response to virus infection, 362–365, 370, 372 helper T cells, 227 functional overview, 2–3 Tregs, 227 helper T cell interferon regulatory factor regulation, 211–212 differentiation role, 12–13, 15–16 posttranslational modification, 220 fate determination, 329 receptor history of study, 1–2 activation, 224 innate lymphoid cell regulation, 381–382, 386 signaling pathway, 223, 225 natural killer cell function, 18 structure and function, 221–223 receptors, 1–2, 5–6 types, 175 regulatory T-cell regulation, 346–350 virus infection treatment, 175–176 therapy, 22–25 Interferon regulatory factor (IRF) Treg function, 11–12, 14–15 interferon-g regulation, 211–212 Interleukin-3 (IL-3) structure, 206 cancer studies, 46 type I interferon regulation functional overview, 44 cytosolic DNA recognition, 210–211 nervous system function, 46–47 cytosolic RNA recognition, 208–210 receptor, 48–53 Toll-like receptor signaling, 206–208 sepsis and inflammation role, 45 type III interferon regulation, 212 therapeutic targeting, 55 types, 206 Interleukin-4 (IL-4) Interleukin-1 (IL-1) B-cell function, 16–18 autoinflammatory disease studies functional overview, 3–4 cryopyrin-associated periodic syndromes, 262–263 innate lymphoid cell regulation, 384–385 extrinsic inflammasomopathies, 265–267 macrophage function, 19 familial Mediterranean fever, 263–264 natural killer cell function, 18–19 465 © 2018 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Cytokines: From Basic Mechanisms of Control to New Therapeutics. Click here for more information on how to buy the book. Index Interleukin-4 (IL-4) (Continued) cellular sources, 160 receptors, 6 family members, 157–159 T helper cell differentiation role, 12–14, 329 receptors, 158–159 therapy, 25 structure, 158 Interleukin-5 (IL-5) systemic lupus erythematosus therapeutic targeting, 163 functional overview, 44 therapy innate lymphoid cell regulation, 384, 389 Crohn’s disease, 159, 161–162 nervous system function, 46–47 mechanism